PD-1(L1)/VEGF双抗:多项NSCLCIII期临床达到PFS终点 结直肠癌等肿瘤一线临床获益明显

山西证券
10 Jul

药物点评:PD-1(L1)/VEGF 双抗是潜在肿瘤免疫基石药物。PD-1(L1)/VEGF 双抗对抗血管和免疫检查点协同抑制,增强肿瘤组织滞留能力和疗效,可治疗多种肿瘤。首款PD-1/VEGF 双抗康方生物-依沃西单抗在EGFR-TKI 经治非鳞状NSCLC、一线PD-L1 阳性NSCLC 中国上市,在NSCLC 等超6 种一线癌症III 期临床。PD-L1/VEGF 双抗百时美施贵宝-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10